Background Currently, there is no comprehensive and multidisciplinary recommendation study covering all aspects of pediatric dysphagia (PD). This study aimed to generate PD management recommendations with methods that can be used in clinical practice to fill this gap in our country and in the world, from the perspective of experienced multidisciplinary experts. Methods This recommendation paper was generated by a multidisciplinary team, using the seven-step process and a three-round modified Delphi survey via e-mail. First, ten open-ended questions were created, and then detailed recommendations including management, diagnosis, treatment, and follow-up were created with the answers from these questions. Each recommendation item was voted on by the experts as overall consensus (strong recommendation), approaching consensus (weak recommendation) and divergent consensus (not recommended). Results In the 1st Delphi round, a questionnaire of 414 items was prepared based on the experts’ responses to ten open-ended questions. In the 2nd Delphi round, 59.2% of these items were accepted as pre-recommendation. In the 3rd Delphi round, 62.6% of 246 items were accepted for inclusion in the proposals. The final version recommendations consisted of 154 items. Conclusions This study includes comprehensive and detailed answers for every problem that could be posed in clinical practice for the management of PD, and recommendations are for all pediatric patients with both oropharyngeal and esophageal dysphagia.
Regenerative endodontic treatment (RET) is a biologically based approach aiming to restore the pulp–dentin complex in immature permanent teeth with necrotic pulps. In this procedure, a blood clot is induced within the canal to serve as a scaffold supporting stem cell migration, and its stability and regenerative success are closely linked to dentin surface morphology. This study focused exclusively on the quantitative assessment of surface roughness, without evaluating biological outcomes such as cellular response or long-term clot stability, and aimed to evaluate the effects of 17
1001 Background: Imlunestrant (imlu) is a next-generation, brain-penetrant, oral selective estrogen receptor degrader. The EMBER-3 trial, in patients (pts) with ER+, HER2- ABC who had disease progression on or after aromatase inhibitor-based therapy, showed significant progression free survival (PFS) improvement with imlu vs standard therapy (SOC, fulvestrant or exemestane) in pts with ESR1 mutations ( ESR1 m), and with imlunestrant+abemaciclib (imlu+abema) vs imlu in all pts, regardless of ESR1 m. Exploratory PRO analyses are presented here. Methods: EORTC QLQ-C30 was administered at baseline (BL) and every 8 weeks until treatment discontinuation. Prespecified QLQ-C30 analysis used a longitudinal mixed model for repeated measures to calculate mean change from BL in pts with BL and ≥1 post-BL score. PRO-CTCAE (diarrhea frequency) was administered weekly, reporting 0 (never) to 4 (almost constantly). PRO-CTCAE (injection site reaction [ISR]) was administered to fulvestrant recipients weekly for 2 weeks post-injection, reporting yes/no (pain, swelling, redness). Descriptive analysis was used for PRO-CTCAE. Results: In pts with ESR1 m, imlu monotherapy was associated with many improved or maintained EORTC QLQ-C30 scores, whereas scores with SOC were declined or maintained. Specifically, pts with ESR1 m on imlu had improved global health status (GHS)/quality of life (QOL) and physical function (PF) scores, while scores with SOC declined (mean change differences between treatments: 9.9 [0.1, 19.7] and 6.2 [-0.8, 13.1], respectively). These PRO findings mirror the PFS findings in this group. In the overall population, GHS/QOL scores declined similarly with imlu vs SOC (mean change differences: 0.5 [-4.7, 5.7]), while PF scores were maintained with imlu vs a slight decline with SOC (mean change difference: 2.5 [-1.1, 6.1]). Most fulvestrant recipients (72%) reported ISR at any time while on treatment, with a mean of 31% during the first week of the first 6 cycles. Imlu+abema vs imlu showed broadly similar declines in all pts, with minimal mean change differences in GHS/QOL and PF scores (0.8 [-7.4, 5.9]; -2.2 [-6.6, 2.2], respectively). Pts reported similarly low rates of “frequent” or “almost constant” diarrhea with imlu (3%) and SOC (2%) and higher rates with imlu+abema (22%). Conclusions: PROs from EMBER-3 demonstrated that patients with ESR1 m had better GHS/QOL and PF with imlu vs SOC, mirroring efficacy results. While the frequency of CTCAE defined ISRs was low, the high rate of PRO-CTCAE ISR demonstrates that this clinically relevant adverse event is underappreciated by physicians. Additionally, all pts had generally comparable GHS/QOL and PF with imlu+abema vs imlu. Overall, these results support the efficacy and safety of imlu compared to existing SOC. Clinical trial information: NCT04975308 .
Background A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib to enzalutamide significantly improved imaging-based progression-free survival and overall survival, with the greatest benefit observed in the cohort with alterations in homologous recombination repair genes. Methods In this ongoing, phase 3, double-blind trial assessing talazoparib in patients with metastatic androgen pathway modulation-sensitive [APMS] prostate cancer harboring alterations in homologous recombination repair genes, we randomly assigned patients in a 1:1 ratio to receive talazoparib at a dose of 0.5 mg plus enzalutamide at a dose of 160 mg once daily (talazoparib group) or placebo plus enzalutamide at a dose of 160 mg once daily (control group). Randomization was stratified according to disease status (new or relapsed), disease volume (high or low), and BRCA (vs. non-BRCA) mutation status. The primary end point was investigator-assessed imaging-based progression-free survival. The key secondary end point was overall survival. Results A total of 300 patients were assigned to the talazoparib group and 299 to the control group. At 3 years, progression-free survival was 77% in the talazoparib group and 56% in the control group (hazard ratio for disease progression or death, 0.48; 95% confidence interval [CI], 0.36 to 0.65; P<0.001). In this interim analysis, overall survival at 3 years was 78% in the talazoparib group and 72% in the control group (hazard ratio for death, 0.77; 95% CI, 0.56 to 1.04). Serious adverse events were reported in 42% and 32% of the patients in the talazoparib group and the control group, respectively. In the talazoparib group, the most common adverse events were anemia, fatigue, and decreased neutrophil count, and the most common event of grade 3 or higher was anemia, reported in 51% of the patients; two treatment-related deaths occurred. Conclusions Talazoparib added to enzalutamide led to significantly better imaging-based progression-free survival than placebo plus enzalutamide among patients with metastatic APMS prostate cancer harboring alterations in homologous recombination repair genes. Serious adverse events were more common with talazoparib plus enzalutamide than with placebo plus enzalutamide. (Funded by Pfizer; TALAPRO-3 ClinicalTrials.gov number, NCT04821622.)
Purpose To assess the spectrum of calcification patterns in uterine fibroids using computed tomography (CT) and identify their associations with lesion size, anatomical location, and margin characteristics in a Turkish population. Methods In this retrospective observational study, 140 women aged ≥ 30 years with CT-confirmed calcified uterine fibroids were examined at a tertiary care hospital between January 2020 and December 2025. A non-probability consecutive sampling method was used. The CT images were independently assessed by two experienced radiologists who categorized the fibroids based on size, anatomical location (submucosal, intramural, subserosal, and transmural), lesion margin (well-defined, lobulated, and irregular), and calcification pattern. Calcification patterns were divided into non-coarse (punctate and amorphous) and coarse (peripheral, dense, and popcorn) patterns. Categorical variables were analyzed using the Chi-square and Fisher's exact tests, while continuous variables were evaluated using the Kruskal–Wallis test. Multivariate logistic regression analysis was conducted to determine the independent predictors of coarse calcifications. Statistical significance was set at p < 0.05. Results Amorphous calcifications accounted for 27.2% and peripheral calcifications for 23.8%, making them the most common patterns observed. There was a notable link between the pattern of calcification and its anatomical location (χ²=14.97, p = 0.002; Fisher's exact, p = 0.001). Coarse calcifications were predominantly found in intramural (45.6%) and transmural (10.3%) fibroids, whereas non-coarse patterns were more frequently observed in subserosal and submucosal areas. The size of the lesions varied significantly with different calcification patterns (H = 11.02, p = 0.026), with larger fibroids showing a tendency towards coarser calcification. No significant correlation was found between patient age and the calcification pattern (p = 0.401). In multivariate logistic regression, lesion size was identified as an independent predictor of coarse calcification (OR = 1.54, 95% CI: 1.06–2.22, P = 0.022). Lesions with irregular margins had lower odds of coarse calcification than those with well-defined margins (OR = 0.14, 95% CI: 0.03–0.69, P = 0.015). Conclusion The calcification patterns observed in uterine fibroids are significantly influenced by lesion size and anatomical location. Computed tomography (CT) imaging provides an effective means of characterizing these patterns, potentially aiding clinical decision-making. Notably, larger intramural fibroids are more prone to coarse calcific degeneration.
